Altered receptor binding, antibody evasion and retention of T cell recognition by the SARS-CoV-2 XBB.1.5 spike protein

Altered receptor binding, antibody evasion and retention of T cell recognition by the SARS-CoV-2 XBB.1.5 spike protein

Abstract The XBB.1.5 variant of SARS-CoV-2 has rapidly achieved global dominance and exhibits a high growth advantage over previous variants. Preliminary reports suggest that the success of XBB.1.5 stems from mutations within its spike glycoprotein, causing immune evasion and enhanced receptor bindi...

Bibliográfalaš dieđut
Váldodahkkit:	Dhiraj Mannar, James W. Saville, Chad Poloni, Xing Zhu, Alison Bezeruk, Keith Tidey, Sana Ahmed, Katharine S. Tuttle, Faezeh Vahdatihassani, Spencer Cholak, Laura Cook, Theodore S. Steiner, Sriram Subramaniam
Materiálatiipa:	Artihkal
Giella:	English
Almmustuhtton:	Nature Portfolio 2024-02-01
Ráidu:	Nature Communications
Liŋkkat:	https://doi.org/10.1038/s41467-024-46104-2

Geahča maid

Structural analysis of receptor engagement and antigenic drift within the BA.2 spike protein
Dahkki: James W. Saville, et al.
Almmustuhtton: (2023-01-01)

Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry
Dahkki: Dhiraj Mannar, et al.
Almmustuhtton: (2021-06-01)

Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants
Dahkki: James W. Saville, et al.
Almmustuhtton: (2022-02-01)

Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies.
Dahkki: Xing Zhu, et al.
Almmustuhtton: (2021-04-01)

Continued evasion of neutralizing antibody response by Omicron XBB.1.16
Dahkki: Julia N. Faraone, et al.
Almmustuhtton: (2023-10-01)

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
Dahkki: Julia N. Faraone, et al.
Almmustuhtton: (2023-12-01)

SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization
Dahkki: Dhiraj Mannar, et al.
Almmustuhtton: (2022-08-01)

Single spike mutation differentiating XBB.1 and XBB.1.5 enhances SARS-CoV-2 cell-to-cell transmission and facilitates serum-mediated enhancement
Dahkki: Elena Criscuolo, et al.
Almmustuhtton: (2024-11-01)

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
Dahkki: Nita Patel, et al.
Almmustuhtton: (2023-11-01)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
Dahkki: Rajesh M. Valanparambil, et al.
Almmustuhtton: (2023-11-01)

XBB.1.16‐RBD‐based trimeric protein vaccine can effectively inhibit XBB.1.16‐included XBB subvariant infection
Dahkki: Dandan Peng, et al.
Almmustuhtton: (2024-09-01)

Severity of COVID-19 sub-lineages XBB/XBB 1.5/XBB1.16, EG.5.1. and JN.1. in England
Dahkki: Catherine Quinot, et al.
Almmustuhtton: (2024-08-01)

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
Dahkki: Yanping Hu, et al.
Almmustuhtton: (2023-12-01)

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Dahkki: Panke Qu, et al.
Almmustuhtton: (2023-05-01)

A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
Dahkki: Cai He, et al.
Almmustuhtton: (2023-06-01)

Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients
Dahkki: Martina Brandolini, et al.
Almmustuhtton: (2023-01-01)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
Dahkki: Andrei A. Pochtovyi, et al.
Almmustuhtton: (2023-09-01)

Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection
Dahkki: Jin-Jin Chen, et al.
Almmustuhtton: (2023-04-01)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
Dahkki: Danyi Ao, et al.
Almmustuhtton: (2023-04-01)

The SIV surface spike imaged by electron tomography: one leg or three?
Dahkki: Sriram Subramaniam
Almmustuhtton: (2006-08-01)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
Dahkki: Thirumalaisamy P. Velavan, et al.
Almmustuhtton: (2023-03-01)

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion
Dahkki: Delphine Planas, et al.
Almmustuhtton: (2024-03-01)

Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1
Dahkki: Stephanie K. Lathrop, et al.
Almmustuhtton: (2024-08-01)

Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster
Dahkki: Rafael Rahal Guaragna Machado, et al.
Almmustuhtton: (2024-01-01)

The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells
Dahkki: Joel Sop, et al.
Almmustuhtton: (2025-03-01)

Omicron spike protein: a clue for viral entry and immune evasion
Dahkki: G. M. N. Behrens, et al.
Almmustuhtton: (2022-09-01)

Counterfactual analysis of the 2023 Omicron XBB wave in China
Dahkki: Hengcong Liu, et al.
Almmustuhtton: (2024-03-01)

Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1
Dahkki: Lunzhi Yuan, et al.
Almmustuhtton: (2024-03-01)

Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023
Dahkki: Huan Zhang, et al.
Almmustuhtton: (2024-11-01)

Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination
Dahkki: Rahul K. Suryawanshi, et al.
Almmustuhtton: (2023-12-01)

Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants
Dahkki: Dibya Ghimire, et al.
Almmustuhtton: (2022-06-01)

Spike protein of SARS-CoV-2 Omicron variant: An in-silico study evaluating spike interactions and immune evasion
Dahkki: Jose A. Jimenez Ruiz, et al.
Almmustuhtton: (2022-11-01)

XBB.1.5 emerges in the Americas: what it means to the region
Dahkki: Peter Hotez
Almmustuhtton: (2023-02-01)

An XBB.1.5-based inactivated SARS-CoV-2 vaccine partially protects against XBB.1.5 and JN.1 strains in hamsters
Dahkki: Ryuta Uraki, et al.
Almmustuhtton: (2025-02-01)

Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients
Dahkki: Philippa von der Schulenburg, et al.
Almmustuhtton: (2024-12-01)

Neutralizing antibody responses to three XBB protein vaccines in older adults
Dahkki: Guo-Jian Yang, et al.
Almmustuhtton: (2025-02-01)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
Dahkki: Rachael Pung, et al.
Almmustuhtton: (2023-08-01)

Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?
Dahkki: Jinghao Nicholas Ngiam, et al.
Almmustuhtton: (2024-12-01)

Immunity evasion: consequence of the N501Y mutation of the SARS-CoV-2 spike glycoprotein
Dahkki: Henrietta Onyinye Uzoeto, et al.
Almmustuhtton: (2022-01-01)

Dynamics of SARS-CoV-2 variants during the XBB wave in the Republic of Korea
Dahkki: Jin Sun No, et al.
Almmustuhtton: (2024-12-01)